How should levothyroxine be managed in a patient taking 200 µg daily who has anti‑thyroid peroxidase antibodies >300 IU/mL, TSH 15 mIU/L, and a multinodular thyroid with TI‑RADS 2 on ultrasound?

Increase Levothyroxine Dose Immediately

Your patient has overt hypothyroidism (TSH 15 mIU/L) despite taking 200 mcg levothyroxine daily—the levothyroxine dose must be increased to bring TSH into the reference range. 1

Primary Management Strategy

The guideline is unequivocal: when subclinical or overt hypothyroidism is noted in levothyroxine-treated patients, adjust the dosage to bring serum TSH into the reference range 1. With a TSH of 15 mIU/L, this patient has frank treatment failure requiring immediate dose escalation.

Dose Adjustment Approach

• Increase by 25-50 mcg daily (typical increment for this degree of TSH elevation)
• Recheck TSH in 6-8 weeks after adjustment
• The rapidity depends on age and cardiac comorbidities—proceed cautiously if elderly or cardiac disease present 1

Critical: Rule Out Pseudo-Malabsorption First

Before escalating beyond 250 mcg daily, you must exclude non-adherence (pseudo-malabsorption). This is the most common cause of treatment-refractory hypothyroidism in patients on high doses 2, 3, 4.

Diagnostic Steps for Pseudo-Malabsorption

1. Perform levothyroxine absorption test: Give 1000 mcg oral LT4 load and measure free T4 at baseline and 2-4 hours post-dose

   • Normal absorption: free T4 increases >50% from baseline 2, 3
   • If absorption is normal but TSH remains elevated → confirms non-adherence

2. Verify medication adherence:

   • Pharmacy refill history (unreliable alone)
   • Direct questioning about missed doses
   • Timing relative to food/medications

3. If pseudo-malabsorption confirmed: Consider weekly directly observed therapy (DOT) with 1400 mcg once weekly 3

Address Factors Increasing Levothyroxine Requirements

The high TPO antibody titer (>300 IU/mL) indicates severe Hashimoto's thyroiditis, which is associated with higher levothyroxine requirements 5. Research shows antibody-positive patients require significantly higher daily doses (mean 78.8 vs 64.2 mcg in antibody-negative patients) 5.

Factors to Investigate

• Malabsorption disorders: Celiac disease, atrophic gastritis, H. pylori, inflammatory bowel disease 6
• Interfering medications: Proton pump inhibitors, calcium, iron, bile acid sequestrants, soy products 7
• Timing issues: LT4 must be taken on empty stomach, 30-60 minutes before food 7
• Drug formulation: Consider liquid or softgel formulations if malabsorption suspected 8

The Multinodular Thyroid (TI-RADS 2)

TI-RADS 2 indicates benign nodules—no intervention needed. This finding does not affect levothyroxine management. The multinodular goiter is likely secondary to longstanding Hashimoto's thyroiditis given the markedly elevated TPO antibodies.

Common Pitfalls to Avoid

1. Do not continue escalating doses indefinitely without investigating adherence—patients have been reported on 400+ mcg daily due to unrecognized non-adherence 2

2. Do not assume pharmacy refills equal actual medication intake—this is frequently misleading 3, 4

3. Do not overlook cardiac risk in elderly patients—atrial fibrillation is the most common arrhythmia with levothyroxine overtreatment 7

4. Do not ignore the high antibody titer—this signals more aggressive autoimmune destruction and legitimately higher replacement needs 5

Practical Algorithm

1. Immediate: Increase levothyroxine to 225-250 mcg daily
2. Week 6-8: Recheck TSH, free T4
3. If TSH still elevated on 250+ mcg: Perform LT4 absorption test
4. If absorption normal: Implement adherence strategies (weekly DOT, counseling)
5. If absorption impaired: Investigate GI pathology, switch to liquid/softgel formulation
6. Target TSH: 0.5-2.5 mIU/L (lower half of reference range acceptable if symptomatic) 1

The elevated TPO antibodies will likely persist despite adequate LT4 replacement, though some evidence suggests antibody titers may decrease with treatment 9. However, antibody levels should not guide dosing—TSH normalization is the therapeutic endpoint 1.